RecruitingPhase 1Phase 2NCT07053072

PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.

A Prospective，Single Arm Clinicial Trial Evaluating PD-1 mRNA LNP Vaccine for the Treatment of Advanced Primary Hepatocellular Carcinoma Failing Standard Therapy

Sponsor

West China Hospital

Enrollment

9 participants

Start Date

Oct 23, 2025

Study Type

INTERVENTIONAL

Conditions

Liver Cancer

Summary

Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria10

Male or female patients: ≥18 years of age; ≤70 years of age;
Recurrent or metastatic hepatocellular carcinoma that has failed second-line standard therapy.
Patients with at least one target lesion with a measurable diameter according to the RECIST criteria (CT scan of tumor lesions with a long diameter of ≥10mm, CT scan of lymph node lesions with a short diameter of ≥10mm and a layer thickness of no more than 5mm);
ECOG physical condition score: 0 to 1;
Expected survival ≥ 3 months;
Good function of major organs, i.e., relevant examination indexes within 14 days prior to randomization meet the following requirements:
Routine blood tests: hemoglobin ≥80g/L (no blood transfusion within 14 days); neutrophil count \>1.5×109 /L; platelet count ≥80×109 /L;
Biochemical tests: total bilirubin ≤1.5 × ULN (upper limit of normal); blood alanine aminotransferase (ALT) or blood alanine transaminase (AST) ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN; endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula);
cardiac Doppler ultrasound: left ventricular ejection fraction (LVEF) (LVEF) ≥50%.
Good compliance and family agreement to cooperate in receiving survival follow-up.

Exclusion Criteria14

Participation in a clinical trial of another drug within 4 weeks;
Patients with a prior history of other neoplasms, unless cervical cancer in situ, treated squamous skin cancer or epithelial tumor of the bladder or other malignancies that have undergone radical therapy (at least 5 years prior to enrollment);
Patients with uncontrolled cardiac clinical symptoms or disease, such as NYHA class 2 or higher heart failure, unstable angina pectoris , myocardial infarction within 1 year, clinically significant Supraventricular or ventricular arrhythmias requiring treatment or intervention.
For female subjects: women who are pregnant or breastfeeding.
Patients with active tuberculosis, bacterial or fungal infection (≥ grade 2 of NCI-CTCAE 5.0); HIV infection; active HBV infection; HCV infection.
Those with a history of psychotropic substance abuse that they are unable to abstain from or those with mental disorders;
Subjects with any active autoimmune disease or history of autoimmune disease (e.g., the following, but not limited to : uveitis, enteritis, pituitary gland inflammation, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or asthma that has resolved completely in childhood and does not require any intervention in adulthood may be enrolled; subjects with asthma requiring medical intervention with bronchodilators may not be enrolled).
Patients who have been inoculated with mRNA drugs.
Participation in clinical trials involving lipid nanoparticles, a component of the study vaccine.
Contraindications to intramuscular injection.
History of substance abuse or known medical, psychological or social conditions such as alcohol or drug abuse.
Known allergy, hypersensitivity or intolerance to the investigational vaccine (including any excipients). Previous history of severe allergy to any drug, food, or vaccination, such as anaphylaxis, allergic laryngeal edema, allergic dyspnea, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction).
The female subject is planning to become pregnant or the male subject's partner is planning to become pregnant during the Screening Period and up to 12 months after the full course of drug administration.
In the judgment of the investigator, there is a serious concomitant disease that jeopardizes the patient's safety or interferes with the patient's ability to complete the study.

Interventions

DRUGLow Dose PD-1 mRNA LNP Vaccine

Patients will receive PD-1 mRNA LNP vaccine at 50 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.

DRUGMedium dose PD-1 mRNA LNP vaccines

Patients will receive PD-1 mRNA LNP vaccine at 75 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.

DRUGHigh dose PD-1 mRNA LNP vaccines

Patients will receive PD-1 mRNA LNP vaccine at 100 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.

Locations(2)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Sichuan University West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07053072

Related Trials

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT0407530518 locations

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

NCT060919307 locations